MEPA, short for myoepithelial-pericytic adenoma, is a rare soft tissue tumor that develops from myoepithelial cells, specialized cells found in glands throughout the body. These tumors most commonly appear in or near the salivary glands, though they can also arise in soft tissue elsewhere. Most are benign and slow-growing, but some carry a real risk of becoming malignant, making accurate diagnosis and complete surgical removal important.
Where Myoepithelial Tumors Come From
Myoepithelial cells sit between the inner lining of glands and the surrounding tissue, acting like a muscular wrapper that helps squeeze secretions out. Despite looking like smooth muscle cells under a microscope, they actually originate from the same tissue layer as skin. You have myoepithelial cells in your salivary glands, sweat glands, tear glands, mammary glands, and prostate gland.
When these cells grow abnormally, they can form several tumor types: mixed tumors (also called chondroid syringomas), myoepitheliomas, and, in more aggressive cases, myoepithelial carcinomas. The cells themselves are shape-shifters, taking on at least five distinct forms under a microscope, from spindle-shaped to clear and glassy. This variability is one of the main reasons these tumors are difficult to diagnose correctly.
How These Tumors Typically Present
Most people notice a painless lump, often near the jaw or in the neck, that has been slowly growing over weeks to months. The parotid gland (the large salivary gland in front of each ear) is one of the most common sites. Some patients go months or even years before seeking a diagnosis because the mass doesn’t cause obvious problems.
When symptoms do appear, they can include facial weakness or pain near the tumor site. In rarer locations, such as the airway, patients may develop a cough, shortness of breath, or fever. The average age at diagnosis for the malignant variant is around 50 to 62 years, though the full range spans from 30 to 70. About 20% of soft tissue myoepithelial tumors occur in children, and notably, pediatric cases are more frequently malignant.
Benign Versus Malignant: What Determines the Risk
The distinction between a benign myoepithelioma and a myoepithelial carcinoma comes down to how abnormal the cells look under a microscope. Tumors with at least moderate cellular irregularity are classified as malignant. This matters because the two categories behave very differently.
Benign mixed tumors and myoepitheliomas recur in up to 20% of cases, almost always because the initial surgery didn’t remove every last bit of tumor tissue. They do not spread to other parts of the body. Myoepithelial carcinomas, on the other hand, recur in 39 to 42% of cases and spread to distant organs in 32 to 52% of patients. In a study of pediatric myoepithelial carcinoma patients with follow-up data, 52% developed distant metastases and 43% died from the disease.
How MEPA Is Diagnosed
Because myoepithelial cells can take on so many different appearances, a standard tissue biopsy alone is often not enough to confirm the diagnosis. Pathologists rely on specialized staining techniques that highlight proteins characteristic of myoepithelial cells, including S100, calponin, and certain keratin markers. The presence or absence of these proteins helps distinguish myoepithelial tumors from other growths that may look similar.
Imaging also plays a role. On MRI, these tumors typically appear as well-defined masses with clear borders and a surrounding capsule. A distinctive feature is a multinodular internal structure with visible dividing walls, a pattern that has not been reported in other types of parotid gland tumors. This feature alone can point radiologists toward the correct diagnosis before surgery. On a specific type of MRI scan that measures how freely water moves through tissue, myoepithelial tumors tend to show more restricted movement than the more common pleomorphic adenomas, reflecting their denser cell packing.
Surgical Treatment and Recurrence
Surgery with clear margins is the standard treatment. The goal is to remove the entire tumor along with a buffer of normal tissue around it, confirmed by a pathologist examining the edges of the removed specimen. When margins are clear (meaning no tumor cells are found at the cut edges), the chance of recurrence drops significantly.
Achieving clean margins is not always straightforward. Tumors near the facial nerve, for example, pose a dilemma: cutting too aggressively risks permanent facial paralysis, but leaving tumor cells behind invites recurrence. In one documented case, a parotid gland tumor recurred specifically because surgeons preserved the facial nerve during the first operation, leaving a positive margin. The recurrent mass was later removed under local anesthesia with clear margins.
For benign tumors, complete excision is generally curative. Up to 18% of myoepitheliomas recur, and the risk climbs with incomplete removal. For malignant tumors, the picture is more complicated. Even with clean margins, recurrence and spread remain possible, and additional treatment may be considered based on the aggressiveness of the individual tumor.
Other Meanings of MEPA
Outside of pathology, the abbreviation MEPA appears in a few other contexts. In bone biology, MEPE (matrix extracellular phosphoglycoprotein, sometimes referenced as MEPA) is a protein that helps regulate how your bones mineralize and how your body handles phosphate. It works alongside other hormones and enzymes to control bone density. Mice that lack this protein are resistant to age-related bone loss, and in humans, abnormal levels of MEPE-related molecules have been linked to a condition called oncogenic osteomalacia, where tumors cause the bones to soften.
In toxicology, MPA (methylphosphonic acid) is the final breakdown product of the nerve agent sarin. Detecting it in urine samples allows forensic scientists to confirm exposure. During the 1994 Matsumoto sarin attack in Japan, researchers measured sarin metabolites in victims’ urine up to seven days after exposure, helping estimate how much nerve agent each person had inhaled.
In healthcare administration, MEPA can refer to Medical Emergency Preparedness Assessments, which are audits that evaluate how well hospitals and clinics are prepared for disasters. The Centers for Medicare and Medicaid Services requires healthcare facilities to maintain emergency preparedness plans, communication plans, and testing protocols as a condition of participation in federal programs.